Picture of Adaptive Biotechnologies logo

ADPT Adaptive Biotechnologies Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Momentum

Relative Strength (%)
1m-17.57%
3m-40.29%
6m-47.04%
1yr-68.65%
Volume Change (%)
10d/3m-8.2%
Price vs... (%)
52w High-64.32%
50d MA-15.28%
200d MA-38.68%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-39.61%
Return on Equity-58.31%
Operating Margin-133.33%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Adaptive Biotechnologies EPS forecast chart

Profile Summary

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
September 8th, 2009
Public Since
June 27th, 2019
No. of Shareholders
85
No. of Employees
709
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
145,092,271

ADPT Share Price Performance

Upcoming Events for ADPT

Q1 2024 Adaptive Biotechnologies Corp Earnings Release

Adaptive Biotechnologies Corp Annual Shareholders Meeting

Q2 2024 Adaptive Biotechnologies Corp Earnings Release

Similar to ADPT

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ